Glaucoma News

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Cody McKenzie of Glaukos discusses the anticipated impact of the iDose TR, which launched during the meeting.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Pete England, vice president of global marketing at ViaLase, discusses the company’s femtosecond laser platform for the treatment of open-angle glaucoma.

TAMPA, Fla. — In a presentation from Telling It Like It Is, Analisa Arosemena, MD, discussed the path to achieving 24/7 IOP control for patients with glaucoma and the role that canaloplasty may play.

Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.

ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.

The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.

Both healthy individuals and patients with medically controlled primary open-angle glaucoma experienced a rise in IOP while reading, especially when reading from a smartphone, according to a study published in the Journal of Glaucoma.

The American Optometric Association has released a new, evidence-based clinical practice guideline draft, “Care of the Patient with Primary Open-Angle Glaucoma,” which is available online for peer and public review through April 24.

Glaucoma appeared tied to significant costs not only for individuals, but also for society as a result of premature retirement and loss of productivity, according to a study conducted in Finland and published in PLOS One.

Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops, according to a study.